Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VICHEM CHEMIE RESEARCH, LTD. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action, which represents the current workload for the company's patent prosecution. This 1 pending office action indicates a very specific and limited engagement with the patent office at this time. The prosecution is characterized by high concentration, as there is 1 distinct examiner involved.
This examiner, KOSTURKO, GEORGE W, is responsible for the 1 busiest examiner pending action. Furthermore, the portfolio's activity is restricted to 1 distinct art unit, ensuring that all current examination occurs within a technical framework in the Biotechnology & Pharmaceuticals sector. KOSTURKO, GEORGE W serves as the gatekeeper for this portfolio's current pending matters. For legal strategy, the reliance on 1 distinct examiner and 1 distinct art unit means that the prosecution of the 1 pending office action will not be influenced by varying standards across different units.
This concentration provides a clear focus for the applicant, as the 1 pending office action is not distributed among multiple examiners. Practitioners can dedicate their resources to understanding the specific requirements of the 1 distinct art unit. Such a streamlined profile allows for a more efficient response process, as the company only needs to address the concerns of KOSTURKO, GEORGE W to advance its intellectual property goals within the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSTURKO, GEORGE W | 1 | 54.7% | +49.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261563 | INHIBITORS OF DYRK AND PIM | KOSTURKO, GEORGE W | 29d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18261563 | INHIBITORS OF DYRK AND PIM | KOSTURKO, GEORGE W | 1621 | §102 | Final Rejection | 29d | Pending | Jul 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial